Basic Information
ID DDInter955 and DDInter953
Interaction INTERVAL: Iodine-containing products may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides. These effects may last up to 8 weeks.
Management Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.
References [1] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ. [2] Cerner Multum, Inc. "Australian Product Information." O 0 [3] "Product Information. Sodium Iodide I-123 (sodium iodide I-123)." GE Healthcare, Princeton, NJ. [4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Alternative for Iodine D08A
Povidone-iodine Chlorhexidine Ethanol
Alternative for Iodide I-123 -
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.